Results 21 to 30 of about 5,314 (201)

Hepatitis C virus resistance to the new direct-acting antivirals [PDF]

, 2016
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella, Soriano, Vicente, Trinks, Julieta   +2 more
core   +1 more source

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies [PDF]

, 2018
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs).
Bagaglio, Black, Calleja, Chen, Dietz, Foster, Kalaghatgi, Lindström, Nelson, Palladino, Paolucci, Pawlotsky, Plaza, Poveda, Poveda, Pérez, Sarrazin, Wyles, Zeuzem, Zeuzem, Zeuzem   +20 more
core   +2 more sources

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).

PLoS ONE, 2023
BackgroundHepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma. Globally, nearly 71 million people have chronic HCV infection, and approximately 399,000 dies annually.
Ashish Awasthi, Harshita Katiyar, Sumit Rungta, Amar Deep, Vinod Kumar, Shalimar, Ajay Kumar, Prachi Tiwari, Amit Goel   +8 more
doaj   +1 more source

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs

PLoS ONE, 2023
Background Insurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L. Zullig   +3 more
doaj   +3 more sources

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]

, 2017
Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero, Burra, Patrizia, De Rui, Michele, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Montagnese, Sara, Russo, Francesco Paolo, Senzolo, Marco, Turco, Matteo, Volpato, Sofia, Zanetto, Alberto   +11 more
core   +1 more source

Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort [PDF]

, 2016
[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical
Alonso, S., Ampuero, J., Badia, E., Baliellas, C., Buti, M., Carrión, J.A., Castro-Iglesias, Ángeles, Devesa, M.J., Esteban, R., Fernández, I., Fernández-Carrillo, C., Fernández-Rodríguez, C.M., Gea, F., Granados, R., Gómez, A., Lens, S., Llerena, S., Montero, J.L., Olveira, A., Pascasio, J.M., Planas, J.M.M., Polo, B., Real, Y., Rincón, D., Riveiro-Barciela, M., Rubín, A., Salmerón, J., Turnes, J.   +27 more
core   +2 more sources

Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]

, 2016
Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel), Meer, A.J.P. (Adriaan) van der   +1 more
core   +5 more sources

Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis

The Korean Journal of Gastroenterology, 2016
Articles: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection (N Engl J Med 2015;373:2599-2607) Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection (N Engl J Med 2015;373:2608-2617)
Ki Tae Yoon
doaj   +1 more source

Combination of Direct Antiviral Therapy in Hepatitis C Patients, Population of Karachi

Pakistan Journal of Medicine and Dentistry, 2020
Background: Pakistan has approximately eight million Hepatitis C Virus (HCV) infected patients. Initial regimen of interferon-based along with ribavirin showed SVR (Sustained Virological Response Rate) of up to 50%.
Samia Perwaiz Khan, Muslim Abbas, Ajeet Kumar, Fadieleh A. Sohail, Rubina Ghani   +4 more
doaj   +1 more source

Efectividad del tratamiento de la hepatitis C en pacientes atendidos en la consulta de atención farmacéutica

Ars Pharmaceutica, 2020
RESUMEN Objetivos: Determinar la efectividad del tratamiento de la hepatitis C crónica definida como la respuesta viral sostenida a las 12 semanas (RVS12) tras la finalización del tratamiento con fármacos antivirales de acción directa (AAD ...
José Miguel Sotoca-Momblona, Montserrat Rodriguez-Reyes, Neus Pagès-Puigdemont, Concepció Bartres-Viñas, Sergio Rodriguez-Tajes, Sabela Lens-García, Zoe Mariño-Mendez   +6 more
doaj   +1 more source